Literature DB >> 15063083

Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future.

Magnus Ingelman-Sundberg1.   

Abstract

The field of cytochrome P450 pharmacogenetics has progressed rapidly during the past 25 years. All the major human drug-metabolizing P450 enzymes have been identified and cloned, and the major gene variants that cause inter-individual variability in drug response and are related to adverse drug reactions have been identified. This information now provides the basis for the use of predictive pharmacogenetics to yield drug therapies that are more efficient and safer. Today, we understand which drugs warrant dosing based on pharmacogenetics to improve drug treatment. It is anticipated that, in the future, genotyping could be used to personalize drug treatment for vast numbers of subjects, decreasing the cost of drug treatment and increasing the efficacy of drugs and health in general. I estimate that such personalized P450 gene-based treatment would be relevant for 10-20% of all drug therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15063083     DOI: 10.1016/j.tips.2004.02.007

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  146 in total

1.  Variants of glutathione s-transferase pi 1 exhibit differential enzymatic activity and inhibition by heavy metals.

Authors:  Jaclyn M Goodrich; Niladri Basu
Journal:  Toxicol In Vitro       Date:  2012-02-28       Impact factor: 3.500

Review 2.  P450 monooxygenases (P450ome) of the model white rot fungus Phanerochaete chrysosporium.

Authors:  Khajamohiddin Syed; Jagjit S Yadav
Journal:  Crit Rev Microbiol       Date:  2012-05-25       Impact factor: 7.624

3.  Technologies in the Whole-Genome Age: MALDI-TOF-Based Genotyping.

Authors:  Nicolas Vogel; Katrin Schiebel; Andreas Humeny
Journal:  Transfus Med Hemother       Date:  2009-07-10       Impact factor: 3.747

4.  Pharmacogenetic comparison of CYP2D6 predictive and measured phenotypes in a South African cohort.

Authors:  T M Dodgen; C De J Labuschagne; A van Schalkwyk; F E Steffens; A Gaedigk; A D Cromarty; M Alessandrini; M S Pepper
Journal:  Pharmacogenomics J       Date:  2015-10-27       Impact factor: 3.550

Review 5.  Alternative Sampling Strategies for Cytochrome P450 Phenotyping.

Authors:  Pieter M M De Kesel; Willy E Lambert; Christophe P Stove
Journal:  Clin Pharmacokinet       Date:  2016-02       Impact factor: 6.447

6.  Analysis of genetic variations in CYP2C9, CYP2C19, CYP2D6 and CYP3A5 genes using oligonucleotide microarray.

Authors:  Yuanyuan Dong; Huasheng Xiao; Qi Wang; Chunxiu Zhang; Xiuming Liu; Na Yao; Haihui Sheng; Haiyan Li
Journal:  Int J Clin Exp Med       Date:  2015-10-15

7.  Nitric oxide-dependent proteasomal degradation of cytochrome P450 2B proteins.

Authors:  Choon-Myung Lee; Bong-Yoon Kim; Lian Li; Edward T Morgan
Journal:  J Biol Chem       Date:  2007-11-09       Impact factor: 5.157

8.  Pharmacogenetics and other reasons why drugs can fail in pregnancy: higher dose or different drug?

Authors:  David M Haas; Mary DʼAlton
Journal:  Obstet Gynecol       Date:  2012-11       Impact factor: 7.661

9.  Extraadrenal 21-hydroxylation by CYP2C19 and CYP3A4: effect on 21-hydroxylase deficiency.

Authors:  Larissa G Gomes; Ningwu Huang; Vishal Agrawal; Berenice B Mendonça; Tania A S S Bachega; Walter L Miller
Journal:  J Clin Endocrinol Metab       Date:  2008-10-28       Impact factor: 5.958

10.  Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients.

Authors:  Silvana Borges; Zeruesenay Desta; Yan Jin; Azzouz Faouzi; Jason D Robarge; Sanosh Philips; Santosh Philip; Anne Nguyen; Vered Stearns; Daniel Hayes; James M Rae; Todd C Skaar; David A Flockhart; Lang Li
Journal:  J Clin Pharmacol       Date:  2010-01-15       Impact factor: 3.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.